Genomic Expression is a biotechnology startup focused on revolutionizing cancer treatment and viral diagnostics through advanced RNA analysis. The company operates in the healthcare and biotechnology market, primarily serving medical professionals, research institutions, and diagnostic labs. Their core product is a comprehensive RNA test that provides detailed insights into cancer and viral infections, such as COVID-19. This test is designed to detect active infections by analyzing RNA from viruses in upper respiratory samples, which is crucial for accurate diagnosis and treatment planning.

The business model of Genomic Expression is based on providing high-precision diagnostic tests to healthcare providers and researchers. They generate revenue through the sale of their RNA testing kits and services, which are processed in their CLIA-certified lab. The company also offers a Viral Transport Medium that stabilizes viral RNA for shipping at ambient temperatures, ensuring the integrity of samples during transportation.

Genomic Expression has garnered significant attention and investment from notable entities, including Biogen founders and impact investors like Investor Circle and Pipeline Angels. Their leadership team boasts extensive experience in biotechnology and corporate development, with CEO Gitte Pedersen having a background at NovoZymes and advisory roles for the Danish Government. The company has also achieved recognition in various prestigious competitions and conferences, underscoring their innovative approach and market potential.

In summary, Genomic Expression is a cutting-edge biotech firm specializing in RNA-based diagnostics for cancer and viral infections. They serve healthcare providers and researchers, operating in the dynamic healthcare and biotechnology market. Their revenue model revolves around the sale of diagnostic tests and related services, supported by a robust team and strong investor backing.

Keywords: Biotechnology, RNA analysis, Cancer diagnostics, Viral diagnostics, Healthcare, Innovation, CLIA lab, Impact investors, Comprehensive testing, Genomic technologies.